DE60213596D1 - Abin zum schutz gegen hepatitis - Google Patents

Abin zum schutz gegen hepatitis

Info

Publication number
DE60213596D1
DE60213596D1 DE60213596T DE60213596T DE60213596D1 DE 60213596 D1 DE60213596 D1 DE 60213596D1 DE 60213596 T DE60213596 T DE 60213596T DE 60213596 T DE60213596 T DE 60213596T DE 60213596 D1 DE60213596 D1 DE 60213596D1
Authority
DE
Germany
Prior art keywords
abin
protection against
against hepatitis
relates
overexpressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213596T
Other languages
English (en)
Other versions
DE60213596T2 (de
Inventor
Rudi Beyaert
Ben Wielockx
Huffel Sofie Van
Filip Delaei
Claude Libert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of DE60213596D1 publication Critical patent/DE60213596D1/de
Application granted granted Critical
Publication of DE60213596T2 publication Critical patent/DE60213596T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE60213596T 2001-06-22 2002-06-20 Abin zum schutz gegen hepatitis Expired - Lifetime DE60213596T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01202414 2001-06-22
EP01202414 2001-06-22
PCT/EP2002/007154 WO2003000280A2 (en) 2001-06-22 2002-06-20 Abin-mediated hepatitis protection

Publications (2)

Publication Number Publication Date
DE60213596D1 true DE60213596D1 (de) 2006-09-14
DE60213596T2 DE60213596T2 (de) 2007-09-13

Family

ID=8180525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213596T Expired - Lifetime DE60213596T2 (de) 2001-06-22 2002-06-20 Abin zum schutz gegen hepatitis

Country Status (9)

Country Link
US (1) US7094756B2 (de)
EP (1) EP1397154B1 (de)
JP (1) JP4252446B2 (de)
AT (1) ATE334696T1 (de)
AU (1) AU2002350412B2 (de)
CA (1) CA2447249A1 (de)
DE (1) DE60213596T2 (de)
ES (1) ES2269736T3 (de)
WO (1) WO2003000280A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60213596T2 (de) 2001-06-22 2007-09-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Abin zum schutz gegen hepatitis
EP1631823A4 (de) * 2003-05-08 2007-07-11 Beth Israel Hospital Neue nf-kappab-regulationsmechanismen
AU2004273686B2 (en) 2003-09-24 2011-03-03 Centre National De La Recherche Scientifique Selective inhibition of NF-kappaB activation by peptides designed to disrupt NEMO oligomerization.
WO2006029981A1 (en) * 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
WO2006108844A1 (en) * 2005-04-14 2006-10-19 Vib Vzw Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
ES2251831T3 (es) * 1998-05-06 2006-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Inhibidores de la activacion de nf-kb.
DE60213596T2 (de) 2001-06-22 2007-09-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Abin zum schutz gegen hepatitis

Also Published As

Publication number Publication date
US20040136978A1 (en) 2004-07-15
WO2003000280A3 (en) 2003-03-20
US7094756B2 (en) 2006-08-22
DE60213596T2 (de) 2007-09-13
EP1397154A2 (de) 2004-03-17
CA2447249A1 (en) 2003-01-03
ATE334696T1 (de) 2006-08-15
JP2004536827A (ja) 2004-12-09
ES2269736T3 (es) 2007-04-01
JP4252446B2 (ja) 2009-04-08
AU2002350412B2 (en) 2006-06-15
WO2003000280A2 (en) 2003-01-03
EP1397154B1 (de) 2006-08-02

Similar Documents

Publication Publication Date Title
CR20120356A (es) Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
PT1268519E (pt) Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
NO20045429L (no) Kombinasjon av organiske forbindelser
ATE550037T1 (de) Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
WO2005051980A8 (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
NO20073105L (no) Pyridazinonforbindelser
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
WO2008021745A3 (en) Hepatitis c virus entry inhibitors
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BRPI0508095A (pt) compostos como inibidores de ns3 serina protease do vìrus da hepatite c
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
EP2361913A8 (de) Antiinfektiöse Mittel
BR0305259A (pt) Inibidores de hcv ns5b polimerase
WO2006060189A3 (en) Curable silicone compositions incorporating a fluorescent detection system
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
MY128138A (en) Method for fighting against arthropods destructive of crops and compositions therefor
ECSP034561A (es) Derivados puente de piperazina
WO2007059221A3 (en) Hepatitis c virus variants
DE60213596D1 (de) Abin zum schutz gegen hepatitis
DE60305884D1 (de) Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition